代表文章:
(1)The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer, Cell Death Differ. 2020 Apr 23,通讯作者。(IF: 15.828, Q1) (2)RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addition survival through inhibiting LKB1-AMPK-axis, Signal Transduction and Targeted Therapy. 2023, 159,通讯作者。(IF: 38.104, Q1) (3)An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer, Theranostics, 2020,10(26),通讯作者。(IF:11.556, Q1)